Navigation Links
Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment
Date:8/4/2009

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix, FIRMAGON has been used by more than 3,000 patients to fight their prostate cancer.

"This treatment was in development by Ferring Pharmaceuticals in the U.S. and Europe for more than a decade," said Wayne Anderson, President and CEO of Ferring Pharmaceuticals Inc., USA. "We launched degarelix prior to receiving approval for its brand name in order to bring the medical community an effective alternative in the treatment of advanced prostate cancer without delay. We plan to continue our research in the area of urology and we expect to introduce additional treatment advances in the future."

FIRMAGON provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth.(1-3) Phase III pivotal studies showed that FIRMAGON is as effective as leuprolide (Lupron Depot(R))* in reducing and sustaining castrate levels of testosterone.(1,2) Suppression of testosterone to castrate levels occurred significantly faster in patients receiving FIRMAGON than in those receiving leuprolide.(1,2) At Day 3 of treatment, the FIRMAGON group achieved a 90 percent decrease in median testosterone levels compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels, a statistically significant result. FIRMAGON was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the FIRMAGON patients maintain
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ferring Donates US$3 Million to the Royal Textile Academy of Bhutan
2. VA Transferring 85.4 Acres from North Chicago VA Medical Center
3. ALL: Boston Archdiocese Reportedly on Track for Abortion Referring Venture
4. Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program
5. Educating referring clinicians about advanced imaging leads to drop in imaging exams
6. Frost & Sullivan Accolade for Ferring Pharmaceuticals
7. Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
8. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
9. Dr. Jan Linhart Now Offerring Unique Laser Teeth Whitening System
10. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
11. Increase in Diagnostic Imaging Fueled by Self-Referring Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Stress ... stress created from everyday life changes can lead to very serious, life-altering events. ... for coping with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State University ... across the country in stemming sexual assaults on their campuses. , The free, ... consortium of sexual assault researchers and student affairs professionals responding to calls by ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... that creates negative pressure inside a wound to remove exudates, fluid, and infectious ... devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit ... and Green Valley Country Club in Lafayette Hill, PA. Over the past 26 years, ... million for programs and services designed to support patients and their families during their ...
(Date:9/1/2015)... ... ... Royal River Natural Foods, a locally-owned independent natural health store in Freeport, ... and found that, among those who had a stroke, people who used multivitamins survived ... the September 2015 issue of “Natural Insights for Well Being,” which Royal River Natural ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... meets tight deadlines and reduces costs , ... Portland, ... announced the launch of its PeerPoint® Medical Review Portal software. ... to send and receive independent medical reviews via the web. ...
... AIDS Vaccine, Microbicide and PrEP Research and Calls for Urgent ... May 18 "It,s an exciting time in HIV prevention ... important HIV prevention research trials this year, as well as ... will yield important answers in the years to come," said ...
... into muscles , , SUNDAY, May 17 -- Raising hopes ... actually work, researchers report they were able to protect ... primate version of HIV. , They did so by ... to the animals, muscles. Typically, vaccines are aimed at ...
... DIEGOA large, well-controlled, multi-national clinical trial program has ... become the first FDA-approved medicine for idiopathic pulmonary ... study program called "CAPACITY," investigators discovered that the ... the deterioration of lung capacity in patients suffering ...
... (May 17, 2009)The COPD Foundation announces launch of the ... WebMD. Development of the Lung Health Check was made ... , The Lung Health Check is an educational platform ... symptoms and risks of developing lung disease, and suggests ...
... to avoid being attacked , , SUNDAY, May 17 (HealthDay News) ... can be unpredictable, warns the American College of Emergency Physicians ... each year, according to the U.S. Centers for Disease Control ... In 2006, more than 31,000 people had to have reconstructive ...
Cached Medicine News:Health News:AllMed's New PeerPoint Medical Review Portal Improves Medical Review Process 2Health News:AllMed's New PeerPoint Medical Review Portal Improves Medical Review Process 3Health News:Piecing Together the HIV Prevention Puzzle 2Health News:Piecing Together the HIV Prevention Puzzle 3Health News:Piecing Together the HIV Prevention Puzzle 4Health News:Vaccine Shields Monkeys From Simian Form of HIV 2Health News:Vaccine Shields Monkeys From Simian Form of HIV 3Health News:Large clinical trial finds pirfenidone may help lung function in IPF patients 2Health News:Large clinical trial finds pirfenidone may help lung function in IPF patients 3Health News:COPD Foundation announces launch of Lung Health Check on WebMD 2Health News:Beware of Dog Bites 2
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: